Literature DB >> 19082803

Effect of Tang No.1 granule (1) in treating patients with impaired glucose tolerance.

Yan WEI1, Yu-zhi HONG, Xun YE.   

Abstract

OBJECTIVE: To observe the therapeutic effect of Tang No.1 granule (1, T1G) in treating patients with impaired glucose tolerance (IGT).
METHODS: One hundred and forty patients with IGT and with Pi-Wei dampness-heat syndrome type were assigned randomly according to their visiting sequence into two equal groups. The control group received only general knowledge about IGT, but to the treated group, based on current knowledge available, T1G was given additionally for 6 months. Changes in related laboratory indexes, including fasting plasma glucose and insulin (FPG and FINS), plasma glucose 2 h after meal (2hPG), glycosylated hemoglobin (HbA1c), serum triglyceride (TG), low density lipoprotein cholesterol (LDL) and insulin resistance index (HOMA-IR), were observed.
RESULTS: The levels of FPG, 2hPG, HbA1c, FINS, TG and HOMA-IR were significantly decreased after treatment in the treated group, showing a significant difference compared to the control group (P<0.01). Among them, HbA1c decreased from 7.08+or-1.41% to 6.56+or-1.29% in the treated group, while in the control group, it decreased from 7.02+or-1.37% to 6.93+or-1.31%. The level of LDL was also reduced in the treated group after treatment (P<0.05). In the treated group, 13 out of 68 patients (19.12%) had their glucose tolerance reversed to normal, while in the control group, only 2/64 (3.1%) got it reverse; a comparison between the two groups in terms of reversion rate showed a significant difference (P<0.01). No severe adverse reaction was found in the therapeutic course.
CONCLUSIONS: T1G has good clinical effect as a treatment intervention for IGT, as it could improve glycometabolism, significantly depress the levels of post-prandial blood sugar and blood lipids, alleviate clinical symptoms of patients, and effectively cut-off and reverse the yielding and development of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082803     DOI: 10.1007/s11655-008-0298-7

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  6 in total

1.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

Authors:  A Mitrakou; D Kelley; M Mokan; T Veneman; T Pangburn; J Reilly; J Gerich
Journal:  N Engl J Med       Date:  1992-01-02       Impact factor: 91.245

2.  Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?

Authors:  J E Shaw; P Z Zimmet; M de Courten; G K Dowse; P Chitson; H Gareeboo; F Hemraj; D Fareed; J Tuomilehto; K G Alberti
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

3.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Authors:  Robert Ratner; Ronald Goldberg; Steven Haffner; Santica Marcovina; Trevor Orchard; Sarah Fowler; Marinella Temprosa
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

4.  [Effect of dietary and/or exercise intervention on incidence of diabetes in 530 subjects with impaired glucose tolerance from 1986-1992].

Authors:  X Pan; G Li; Y Hu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1995-02

5.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

Review 6.  Rosiglitazone for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C Clar; S H Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
  6 in total
  6 in total

1.  Verification of the Efficacy and Safety of Qi-Replenishing Chinese Medicine in Treating Prediabetes: A Meta-Analysis and Literature Review.

Authors:  Shujie Xia; Bizhen Gao; Shujiao Chen; Xuejuan Lin; Ping Zhang; Yujuan Chai; Candong Li; Tetsuya Asakawa
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-10       Impact factor: 2.629

2.  Efficiency and Safety of Chinese Herbal Medicine in the Treatment of Prediabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yanan Song; Haiyan Wang; Lingling Qin; Mei Li; Saiyue Gao; Lili Wu; Tonghua Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-14       Impact factor: 2.629

Review 3.  Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose.

Authors:  Suzanne J Grant; Alan Bensoussan; Dennis Chang; Hosen Kiat; Nerida L Klupp; Jian Ping Liu; Xun Li
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

4.  Effect of Chinese Herbal Medicine Jinlida Granule in Treatment of Patients with Impaired Glucose Tolerance.

Authors:  Ya-Lin Shi; Wen-Juan Liu; Xiao-Fang Zhang; Wei-Juan Su; Ning-Ning Chen; Shu-Hua Lu; Li-Ying Wang; Xiu-Lin Shi; Zhi-Bin Li; Shu-Yu Yang
Journal:  Chin Med J (Engl)       Date:  2016-10-05       Impact factor: 2.628

Review 5.  Efficacy of Chinese herbal medicine for stroke modifiable risk factors: a systematic review.

Authors:  Wenbo Peng; Romy Lauche; Caleb Ferguson; Jane Frawley; Jon Adams; David Sibbritt
Journal:  Chin Med       Date:  2017-09-05       Impact factor: 5.455

6.  Toward integrated and sustainable prevention against diabetes in rural China: study rationale and protocol of eCROPS.

Authors:  Rui Feng; Kaichun Li; Jing Cheng; Shaoyu Xie; Jing Chai; Pingfu Wei; Debin Wang
Journal:  BMC Endocr Disord       Date:  2013-08-07       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.